Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.89 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.89 |
| ▸ | RECQL | P46063 | 2/20 | 0.89 |
| ▸ | MAOA | P21397 | 2/20 | 0.89 |
| ▸ | MAOB | P27338 | 2/20 | 0.89 |
| ▸ | BCHE | P06276 | 1/20 | 0.89 |
| ▸ | POLB | P06746 | 1/20 | 0.89 |
| ▸ | ACHE | P22303 | 1/20 | 0.89 |
| ▸ | APEX1 | P27695 | 1/20 | 0.89 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.89 |
| ▸ | CASP1 | P29466 | 1/20 | 0.89 |
| ▸ | BLM | P54132 | 1/20 | 0.89 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.89 |
| ▸ | DHODH | Q02127 | 1/20 | 0.89 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.89 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.89 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzoquinone SCHEMBL11299551 | 1.00 | ALDH1A1 (0.89) | ALDH1A1TDP1RECQLMAOAMAOB | |
| Benzoquinone SCHEMBL18103 | 0.94 | — | — | |
| Benzoquinone SCHEMBL460082 | 0.94 | ALDH1A1 (1.00) | ALDH1A1TDP1RECQLMAOAMAOB | |
| Benzoquinone SCHEMBL5308519 | 0.94 | ALDH1A1 (1.00) | ALDH1A1TDP1RECQLMAOAMAOB | |
| Benzoquinone SCHEMBL3208089 | 0.94 | — | — | |
| Benzoquinone SCHEMBL3235611 | 0.89 | ALDH1A1 (0.89) | ALDH1A1TDP1RECQLMAOAMAOB | |
| Benzoquinone SCHEMBL10379701 | 0.89 | ALDH1A1 (0.89) | ALDH1A1TDP1RECQLMAOAMAOB | |
| Benzoquinone SCHEMBL1642381 | 0.89 | — | — | |
| Benzoquinone SCHEMBL21494172 | 0.89 | — | — | |
| Benzoquinone SCHEMBL11216174 | 0.89 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 255 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3027776-B1 | METHODS AND MOLECULAR PHARMACODYNAMIC BIOMARKERS FOR MULTIPLE SIGNALING PATHWAYS IN RESPONSE TO CARBOXYAMIDOTRIAZOLE OROTATE | TACTICAL THERAPEUTICS INC (US) | 2024-02-07 | — | — | EP | claimed |
| US-10378059-B2 | Methods and molecular pharmacodynamic biomarkers for multiple signaling pathways in response to carboxyamidotriazole orotate | TACTICAL THERAPEUTICS, INC. (US) | 2019-08-13 | — | — | US | claimed |
| US-20240058335-A1 | METHODS FOR TREATMENT OF CANCER USING ABL INHIBITORS AND DRUGS TARGETING THE MEVALONATE PATHWAY | DUKE UNIVERSITY (US) | 2024-02-22 | — | — | US | disclosed |
| US-20240060132-A1 | DIAGNOSIS OF SEPSIS | BECTON DICKINSON CO (US) | 2024-02-22 | — | — | US | disclosed |
| EP-3027776-B1 | METHODS AND MOLECULAR PHARMACODYNAMIC BIOMARKERS FOR MULTIPLE SIGNALING PATHWAYS IN RESPONSE TO CARBOXYAMIDOTRIAZOLE OROTATE | TACTICAL THERAPEUTICS INC (US) | 2024-02-07 | — | — | EP | disclosed |
| US-20230374595-A1 | GENE EXPRESSION PROFILES ASSOCIATED WITH CHRONIC ALLOGRAFT NEPHROPATHY | THE SCRIPPS RESEARCH INSTITUTE | 2023-11-23 | — | — | US | disclosed |
| US-11821037-B2 | Gene expression profiles associated with chronic allograft nephropathy | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-11-21 | — | — | US | disclosed |
| EP-3198007-B1 | METHODS AND COMPOSITIONS FOR MODULATING TH-GM CELL FUNCTION | NAT UNIV SINGAPORE (SG) | 2023-11-01 | — | — | EP | disclosed |
| US-20230323464-A1 | METHOD FOR PREDICTING PROGNOSIS OF PATIENTS HAVING EARLY BREAST CANCER | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2023-10-12 | — | — | US | disclosed |
| US-11644466-B2 | Methods for treating, preventing and predicting risk of developing breast cancer | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-11578367-B2 | Diagnosis of sepsis | BECTON, DICKINSON AND COMPANY (US) | 2023-02-14 | — | — | US | disclosed |
| US-20060246495-A1 | Diagnosis of sepsis | BECTON, DICKINSON AND COMPANY | 2006-11-02 | — | — | US | disclosed |
| WO-2006094286-A2 | ADULT PANCREATIC DERIVED STROMAL CELLS | O'NEIL JOHN (US) | 2006-09-08 | — | — | WO | disclosed |
| US-20060183141-A1 | Gene expression signature for prediction of human cancer progression | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERITY | 2006-08-17 | — | — | US | disclosed |
| US-20060056948-A1 | Methods | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2006-03-16 | — | — | US | disclosed |
| US-20060046259-A1 | Differential expression of molecules associated with acute stroke | THE GOV. OF THE U.S.A AS REPRESENTED BY THE SECRETARY OF THE DEPT. OF HEALTH & HUMAN SERVICES | 2006-03-02 | — | — | US | disclosed |
| US-20060019890-A1 | Method for treating cardiac remodeling following myocardial injury | SCIOIS INC. | 2006-01-26 | — | — | US | disclosed |
| WO-2005116268-A2 | DIFFERENTIAL EXPRESSION OF MOLECULES ASSOCIATED WITH ACUTE STROKE | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH (US) | 2005-12-08 | — | — | WO | disclosed |
| WO-2005070446-A1 | METHOD FOR TREATING CARDIAC REMODELING FOLLOWING MYOCARDIAL INJURY | SCIOS INC. (US) | 2005-08-04 | — | — | WO | disclosed |
| WO-2005003766-A2 | METHODS OF REGULATING METABOLISM AND MITOCHONDRIAL FUNCTION | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240058335-A1 | METHODS FOR TREATMENT OF CANCER USING ABL INHIBITORS AND DRUGS TARGETING THE MEVALONATE PATHWAY | ABL2, ABL1, VAV1 | ALDH1A1 1244/4885TDP1 2702/4885RECQL 2986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.